The first domestically developed and innovated nuclear drug in China has been approved for market launch.

On April 2nd, the National Medical Products Administration approved the application of Foshan Ready Medicines Co., Ltd. for the listing of Technetium-99m PEC-005 Injection and the Technetium-99m PEC-005 Injection Kit for the preparation of the drug, which is used as an auxiliary examination for suspected lung cancer patients with lymph node metastasis. This is the first class I innovative nuclear drug independently developed in China and the world's first broad-spectrum tumor imaging agent used for SPECT imaging. The approval of this product breaks through the bottleneck that nuclear medicine SPECT imaging technology cannot be used for tumor diagnosis, staging, and efficacy monitoring. More importantly, it breaks the dominance of PET imaging technology in the United States in the field of nuclear medicine tumor imaging diagnosis for nearly 30 years, bringing a breakthrough to the field of nuclear medicine.